A highly experienced group of biotech professionals

Next Frontier Biosciences is led by an accomplished management team that has over 80 years of biotech experience. Our CEO previously spent 8 years as Executive Vice President and General Counsel of a public biotech company that he helped take public and sell for $195 million, and our CSO is one of the leading experts in the field of intranasal drug development and delivery systems. Our team provides us with an important competitive advantage that will allow us to successfully execute on our product development and commercialization plans.

Executive Team

Marc Graboyes

Co-Founder & Chief Executive Officer

Mr. Graboyes is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.

Paul Johnson, Ph.D.

Co-Founder & Chief Scientific Officer

Dr. Johnson has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and authored or invented over 100 patents and scientific publications. Dr. Johnson has experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.

Dorothy “Dot” Colagiovanni, Ph.D.

Vice President, Product Development

Dr. Colagiovanni is responsible for the day-to-day management of Next Frontier Biosciences’ research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne. She also held research positions with OSI Pharma, Gilead Sciences and Amgen. Dr. Colagiovanni has a broad range of development experience, starting from early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen Boulder.


Stephen Cape, Ph.D.

Director of Formulation Sciences

Dr. Cape has more than 15 years of experience developing formulations of pharmaceuticals, biologicals, and vaccines for alternative routes of delivery, including sublingual, nasal, transdermal, and inhalation. Prior to joining NFB, he held technical and project leadership roles at the University of Colorado and Aktiv-Dry LLC (Boulder, CO). Dr. Cape led the formulation and spray-drying process development of the first inhaled dry powder measles vaccine to successfully complete a Phase I clinical trial. He has a broad experience in early-stage basic R&D, formulation and process development, and technology transfer for GMP manufacturing.

Peter Johnson

Director of Operations, Next Frontier Biosciences

Mr. Johnson has extensive experience in management, business and facility operations, public relations, and sales. He was the Founder, Owner and Chief Operating Officer of the Medication Company, a fully Licensed medical marijuana facility in Boulder Colorado. He built two facilities from the ground up: The Med Shed dispensary and a separate marijuana plant grow and processing facility; both were fully licensed by the State of Colorado and City of Boulder. He was responsible for all aspects of operations and marketing, acquired all financing, and created a 300+ registered patient base. The Med Shed won the 2011 People’s Choice Award, First Place, as the best MJ dispensary.

Susan Schwarz

Senior Analytical Chemist

Ms. Schwarz is a biotechnology professional with extensive experience in all stages of biopharmaceutical development from drug discovery to cGMP manufacturing. She has utilized numerous types of analytical instrumentation, from classical wet chemistry techniques for USP testing to HPLC, UPLC, and CE for protein characterization and impurity testing. She has held positions from Quality Control Chemist (Somatogen) working with recombinant hemoglobin to Associate Scientist (Amgen) where she helped bring Nplate (treatment for immune thrombocytopenia) from Phase 1 clinical trials to the commercial market.

Scientific Advisory Board

Laurie K Mischley, ND Ph.D. MPH

Scientific Advisor

Dr. Mischley studied naturopathic medicine (ND) at Bastyr University and epidemiology (MPH) and nutritional sciences (PhD) at the University of Washington.


She is Principle Investigator of the Survey of Cannabis Use (www.CannabisSurvey.org), an international study that gives Cannabis users a forum to tell physicians, researchers, policy-makers, and the public why and how they use Cannabis. She has published on the medical use of Cannabis and differing experiences between men and women who use Cannabis. A study on Cannabis use for Parkinson’s disease tremor has recently been completed.


Most of her work is focused on identifying the nutritional requirements unique to individuals with neurodegenerative diseases. She founded the Social Purpose Corporation, NeurRx, developed an outcome measure to assess PD severity, www.PROPD.org, and is author of the books Natural Therapies for Parkinson’s Disease and Survey of Cannabis Use: Confessions, Insights, and Opinions.

Dr. Rav Ivker, D.O.

Scientific Advisor

Dr. Ivker is a holistic family physician, cannabis clinician, health educator, spiritual counselor, author, and health care visionary. In his current practice, Fully Alive Medicine, in Boulder, CO, his primary focus is the treatment and prevention of chronic pain using a holistic approach that includes medical marijuana.


Dr. Ivker has been practicing medicine for nearly 45 years. His original practice, Columbine Medical Center, became the first combined family practice/minor emergency center in Colorado, a forerunner of today’s Urgent Care Centers. He is the Co-founder and Past-president of the American Board of Integrative Holistic Medicine, a Past-pres. of the American Holistic Medical Assoc., and the author of the best-selling, Sinus Survival.


He is currently writing a new book entitled: CANNABIS FOR CHRONIC PAIN: A Proven Prescription for Using Marijuana to Relieve Your Pain & Heal Your Life. The book is being published by Simon & Schuster and will be in the bookstores next Sept.

Shawn Zinnen, Ph.D.

Scientific Advisor

Dr. Zinnen is Chief Executive Officer of MBC Pharma Inc., a pharmaceutical company focused on discovering and developing novel medicines for the treatment of oncology, bone and infectious diseases. Dr. Zinnen is an experienced pharmaceutical executive and discovery scientist with a demonstrated track record of success in preclinical and early-stage clinical drug development. Dr. Zinnen has managed interdisciplinary teams of industry and academic scientists solving pharmacology related problems for diseases ranging from cancer to asthma to macular degeneration.


Prior to joining MBC Pharma, Dr. Zinnen served in various roles of increasing responsibility at Sirna Therapeutics, Inc. (previously Ribozyme Pharmaceuticals Inc.), where he helped advance drug compounds from discovery stage and into human clinical trials. Dr. Zinnen graduated with a Ph.D. in Biochemistry and Genetics from Duke University and conducted post-doctoral research at the University of Colorado at Boulder as an NIH Fellow. He has authored or coauthored 17 papers and 54 patents.